Psyence Biomedical Ltd. (PBMWW) stock
PBMWWNasdaqPharmaceutical PreparationsFiscal year ends March 31Also trades as PBM
$0.01−0.00 (-2.50%)
Close on Oct 30, 2026Market cap –P/E –Yield –
Psyence Biomedical r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2026 it was $1.47M, up 328.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $1.47M | +328.6% |
| FY2025 | Mar 31, 2025 | $342.17K | -64.2% |
| FY2024 | Mar 31, 2024 | $954.59K | -40.7% |
| FY2023 | Mar 31, 2023 | $1.61M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Sep 30, 2025 | $357.44K | – |
| Q2 FY2025 | Sep 30, 2024 | $265.63K | – |